EVALUATION OF THE EFFECT OF NEOVAGANT TREATMENT ON THE SURVIVAL RATE OF ESOPHAGECTOMY PATIENTS FROM 2016 TO 2019

Esophageal cancer is an invasive malignant tumor that kills more than 90% of people with this disease within 5 years. The metastasis rate of esophageal cancer is faster compared to other cancers. The aim of the study was to investigate the effect of neoadjuvant treatment on the survival rate of esophagectomy patients from 2016 to 2019.

In this case-control study, we included 187 patients with esophageal cancer whom underwent neoadjuvant chemoradiotherapy and referred to Imam Khomeini (ra) Hospital in Urmia for esophagectomy between 2015 and 2018. The collected data were analyzed by Kaplan-Meier test using SPSS version 17 software.

A total of 187 patients with esophageal cancer underwent esophagectomy with a mean age of 60.4 ± 10.6 years were included in the study. 61% of the patients were male and 39% were female. 93.2% of preoperative endoscopic reports were consistent with postoperative pathological reports (P <0.05). The frequency of three-year survival was different based on the age of the patients, and the survival of the patients with age group 55-64 years old was higher than the others (P <0.05).

The results of this study showed that the survival of patients based on age in patients with esophageal cancer underwent esophagectomy in two groups of complete and incomplete response to neoadjuvant was not the same, and this difference is significant. Also, survival of the patients in age group 55-64 years is more than others. There was no significant difference between the survival rates of patients in terms of gender and body mass index.